Guerbet unafraid of generic onslaught
This article was originally published in Clinica
Hospital doors may be opened to a flood of generics following the patent expiry on Bracco's imaging agent, iopamidol. "Unlikely," says Philippe Barthelet. "Generics will not be a significant part of the market because of the characteristics of contrast media." Contrast agents require huge quantities of active ingredients compared with therapeutic pharma- ceuticals. In addition, Mr Barthelet says the significant investment required and relatively low profit margins will deter generic manufacturers.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.